There's no cure or approved disease-modifying drug for Multiple System Atrophy (MSA) yet, but new treatments are in advanced clinical trials, with ATH434 (Alterity Therapeutics), emrusolmin (Teva), and amlenetug (Lundbeck) showing promise by targeting alpha-synuclein protein buildup or iron imbalance, aiming to slow progression, not just manage symptoms. These investigational drugs are in Phase 2/3 trials and have received FDA Fast Track designation, bringing hope for the first disease-modifying therapy.
The U.S. FDA granted Orphan Drug designation to emrusolmin for MSA in 2022. “Multiple System Atrophy is a devastating and rapidly progressive neurodegenerative disorder with no cure,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
Fox takes the drug Sinemet (levodopa-carbidopa). It controls some of the milder symptoms, including, "the constant rigidity of his hips, tremors in one or both hands, and a 'tapping' feeling in his feet." Mr. Fox reportedly has also had brain surgery (on the thalamus) to try to relieve his tremors.
Medicines that treat Parkinson's disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson's medicines.
Treatment of MSA remains largely supportive. About 30-60% of patients respond to typical Parkinson's medications such as carbidopa/levodopa (Sinemet), and dose trial of up to 1 gram/day of levodopa for a few months is recommended. Benefit seen early in disease often fades though, or becomes fraught with complications.
The approximate rate of effectiveness of levodopa in multiple system atrophy (MSA) has been reported as 30-65% in both clinical and pathological cases (1-3). The pathological background in which levodopa is effective has mainly been studied with a focus on putaminal lesions (4,5).
There are no treatments to cure or stop progression of MSA, but treatments may help manage symptoms and improve quality of life. Oral medications: Medications can help manage MSA symptoms such as movement problems, orthostatic hypotension, urinary urgency and bladder control, and sleep disturbances.
Multiple system atrophy- parkinsonian type (MSA-P) is a rare condition that causes symptoms similar to Parkinson disease. However, people with MSA-P have more widespread damage to the part of the nervous system that regulates important functions such as heart rate, blood pressure, and sweating.
At present, there are no therapies that can reverse or slow the progression of MSA.
Levodopa, considered the 'miracle' drug for treating Parkinson's disease, is still the most effective treatment for managing the motor symptoms of the disease.
Actor Alan Alda has Parkinson's disease, a neurodegenerative disorder he was diagnosed with in 2015 but publicly revealed in 2018, noting he also experiences prosopagnosia (face blindness), and he manages these conditions with a positive attitude, staying active, and finding humor, despite the challenges to his hands, legs, and voice.
The 5-2-1 rule in Parkinson's disease is a clinical guideline to identify when the condition may be considered "advanced," suggesting a need for advanced therapies like Deep Brain Stimulation (DBS) or intestinal gel. It's met if a patient experiences at least 5 doses of levodopa daily, plus 2 or more hours of "Off" time (symptoms return), and/or 1 or more hour of troublesome dyskinesia (involuntary movements) daily, signaling inadequate symptom control.
Currently, there are no treatments to stop or slow the progression of MSA, and there is no cure. However, there are treatments to help people cope with the symptoms.
Levodopa is the most effective Parkinson's disease medicine. It is a natural chemical that passes into the brain and becomes dopamine. Levodopa is combined with carbidopa to help levodopa reach the brain and to prevent or lessens side effects such as nausea.
Now there is no effective medicine to cure MSA, most part of methods are symptomatic treatment and enhanced care. The main research direction of treatment includes immunization transplantation and cytotherapy.
Causes. Although the cause of MSA is currently unknown, there is evidence that the primary defect occurs in glial cells, a type of cells in the nervous system that support and protect neurons in the brain, and help maintain physiological balance.
Multiple system atrophy (MSA) is a rare neurological disease that causes certain brain areas to deteriorate. Over time, this disrupts abilities and functions handled by those brain areas. This disease is ultimately fatal.
MSA is a terminal disease with an average patient survival of 6 to 10 years after the onset of symptoms.
People typically live about 7 to 10 years after multiple system atrophy symptoms first appear. However, the survival rate with MSA varies widely. Death is often due to trouble breathing, infections or blood clots in the lungs.
Although a few recent studies reported that cognitive impairments could occur in patients with MSA, prominent dementia with progressive decline is not a typical clinical manifestation of MSA. In particular, dementia with MSA-cerebellar type is very rare.
Offer to do the shopping. Help with everyday tasks round the house such as hanging the washing out, doing the hoovering etc. Share your computer and technology skills with them, these can be a lifeline for people with MSA but they may need help learning to use them.
People living with MSA may experience periods of low mood, depression and/or anxiety, yet mental health is often overlooked at routine appointments with health and care professionals. Being able to recognise how MSA is affecting your mental health can help you to seek professional support when needed.
TOP 9 SUPPLEMENTS FOR PARKINSON'S DISEASE TREATMENT
Six months of resistance training with instability alleviate the MSA-related effects and improve the quality of life in a patient with MSA. High complexity exercise intervention (i.e., resistance training with instability) may be very beneficial to individuals with impaired motor control and function as MSA patients.